探讨诱导化疗（IC）联合抗PD-1免疫治疗治疗局部晚期鼻咽癌（LA-NPC）的近期疗效和安全性。 共纳入我院第一附属医院诊断为LA-NPC的217例患者。回顾性入组南昌大学，其中接受IC联合抗PD-1治疗的67例和接受IC治疗的150例。根据 RECIST v1.1 标准，在 IC 周期结束时和放疗后 1 个月评估疗效。急性毒性根据 CTCAE v5.0 标准进行分级。定量变量通过非配对t检验进行比较，分类变量通过Fisher Freeman-Halton检验或Pearson卡方检验进行评估。在所有诱导治疗周期结束时，IC抗PD的客观缓解率（ORR） -1 组为 88.1% (59/67)，而 IC 组为 70.0% (105/150)。亚组分析显示，Ⅲ期和ⅣA期患者在接受抗PD-1治疗后，ORR均取得了显着改善。与 T1-2 或 N0-1 类别的患者相比，T3-4 或 N2-3 类别的患者似乎从抗 PD-1 中获益更多。然而，放疗结束一个月后，两个治疗组之间的 ORR 和完全缓解 (CR) 率均无显着差异。此外，两组中3-4级不良事件的发生频率也相似。与单独使用IC相比，IC联合抗PD-1免疫治疗可显着改善诱导治疗后LA-NPC患者的ORR。版权所有©2024。由爱思唯尔有限公司

To investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with anti-PD-1 immunotherapy in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).A total of 217 patients diagnosed with LA-NPC at the First Affiliated Hospital of Nanchang University, including 67 who received IC combined with anti-PD-1 and 150 who received IC, were retrospectively enrolled. Efficacy was evaluated at the end of the IC cycles and one month after radiotherapy based on RECIST v1.1 criteria. Acute toxicities were graded based on the CTCAE v5.0 criteria. Quantitative variables were compared by unpaired t-tests, and categorical variables were evaluated by Fisher Freeman-Halton test or Pearson Chi-square test.At the end of all induction therapy cycles, the objective response rate (ORR) of the IC + anti-PD-1 group was 88.1 % (59/67) as opposed to 70.0 % (105/150) in the IC group. Subgroup analysis showed that patients in both stage Ⅲ and ⅣA achieved a significant improvement in ORR with the inclusion of anti-PD-1 therapy. Patients with T3-4 or N2-3 category appeared to benefit more from anti-PD-1 compared to patients with T1-2 or N0-1 category. However, neither ORR nor the complete response (CR) rate was significantly different between the two treatment groups one month after the end of radiotherapy. In addition, the frequency of Grade 3-4 adverse events were also similar in both groups.IC combined with anti-PD-1 immunotherapy significantly improved the ORR of LA-NPC patients after induction therapy compared to IC alone.Copyright © 2024. Published by Elsevier Ltd.